Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Alliance BioBank Inks Deal for First Genetic Trust Technology

NEW YORK, May 2 (GenomeWeb News) - The Genetic Alliance BioBank has formed a partnership with First Genetic Trust to develop tissue banking and clinical research capabilities, the company said today.

 

Terms of the deal call for First Genetic Trust to help GAB develop information technology infrastructure for managing its tissue and data banking, and for executing clinical drug studies. First Genetic Trust's technology will initially be used to manage collaborative research programs within and across the National Psoriasis Foundation, the Inflammatory Breast Cancer Research Foundation, and PXE International, GAB added.

 

Specifically, First Genetic Trust will use its web-based enTrust Genetic Banking and Study Management system to help the research institutes create central repositories of well-phenotyped patients, with essential genetic and biologic samples, GAB said.

 

Specific terms of GAB's deal with First Genetic Trust were not disclosed.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.